As ATRA elevates CD38 expression and enhances the therapeutic benefit of daratumumab against MM cell lines, primary MM cells, and MM tumors in a humanized MM mouse model patients [20], we evaluated the potential of ATRA in CD38 upregulation in CD38low lymphoid cancer cells. This evidence concerns the gene CD38 and lymphoma.